Welcome!

News Feed Item

Panther Biotechnology, Inc. Announces the Appointment of Two Directors and Securing an Option on a Potential Blockbuster Novel Oncology Small Molecule With Northwestern University That Panther Will Fast Track Into the Clinic

CHICAGO, IL -- (Marketwired) -- 08/26/14 -- Panther Biotechnology, Inc. (OTCQB: PBYA) announced today the appointments of Mr. David Barshis and Mr. James Sapirstein to the company's Board of Directors. In addition the Panther announced it has secured an option agreement on a license for its lead technology, Numonafide a potential blockbuster novel small molecule compound in the liquid and solid tumor cancer market place, with Northwestern University.

Mr. Barshis has over twenty-five year's entrepreneurial experiences in organizing and managing life science ventures in the U.S. and internationally. He has developed multiple start-up companies from the ground up and developed them into publicly traded entities on the U.S. and Canadian stock exchanges. Mr. Sapirstein brings over thirty years of pharmaceutical industry experience to the Company having served in various roles in research, development and sales. More recently James served as Chief Executive Officer to a number of biotechnology and healthcare companies from start-ups to fully operational and profitable entities. Full biographies are posted on the Company's web site www.pantherbiotechnology.com.

Irwin Zalcberg, Chairman of Panther, commented, "With the additions of David and James we have advanced our goals of organizing a team necessary to oversee, evaluate and assist in the execution of our plans to begin to develop important cancer treatments and shepherd these treatments through early and later stage clinical studies. Adding the strong backgrounds in research, clinical development, management and pharmaceutical industry expertise we feel we are poised to move Panther into a fully functioning drug development company."

In addition the Company is announcing it has secured an option on a license and is working on finalizing the formal license for its lead technology candidate, Numonafide, from Northwestern University. Numonafide, a derivative of the widely studied drug Amonafide, is a DNA intercalator and topoisomerase 2 inhibitor. Through research completed at Northwestern University this derivative has shown to compose all of the positive cancer inhibitory abilities of Amonafide while avoiding the toxic metabolism demonstrated with the Drug. Dr. Jayesh Mehta, M.D. Director of Panther, commented, "We have been evaluating the positive in-vitro and in-vivo results being achieved with this technology and are looking to accelerate its development into human clinical studies. We look forward to partnering with Northwestern University to complete pre-clinical development activities and prepare this drug for introduction to patients."

Panther Biotechnology, Inc.

Panther Biotechnology is a newly formed entity focused on the acquisition and development of therapeutics for the treatment of leukemia, lymphoma, myeloma and other cancers. The Company will focus on identifying promising anti-cancer therapeutic candidate that are optimized derivatives of widely studied products or re-purposed existing marketed compounds. The first product candidate, Numonafide, will be evaluated for the treatment of patients with Acute Myeloid Leukemia (AML). The AML market is anticipated to grow to $1.67 billion dollars by 2020 in G8 countries and it is Panthers belief that there are insufficient treatment options available to treat patients.

Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Panther cannot ensure that it will be able to achieve a license for Numonafide on a commercially acceptable or reasonable basis and may not be able to attract the necessary funding to advance the project in a timely manner. In addition, Panther cannot ensure that clinical results related to in-vivo and in-vitro studies of Numonafide will reproduce the positive results achieved to date. Finally, Panther cannot be sure that it will be able to obtain regulatory approval for the commercial marketing of its treatment for Patients with AML and there may be other treatments in development that are approved before Panthers.

Contact:
Richard P. Rainey
Chief Executive Officer
(570) 343-9867


More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...
SYS-CON Events announced today that Elastifile will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Elastifile Cloud File System (ECFS) is software-defined data infrastructure designed for seamless and efficient management of dynamic workloads across heterogeneous environments. Elastifile provides the architecture needed to optimize your hybrid cloud environment, by facilitating efficient...
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, discussed the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insights from the vast t...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
Recently, IoT seems emerging as a solution vehicle for data analytics on real-world scenarios from setting a room temperature setting to predicting a component failure of an aircraft. Compared with developing an application or deploying a cloud service, is an IoT solution unique? If so, how? How does a typical IoT solution architecture consist? And what are the essential components and how are they relevant to each other? How does the security play out? What are the best practices in formulating...
SYS-CON Events announced today that Golden Gate University will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Since 1901, non-profit Golden Gate University (GGU) has been helping adults achieve their professional goals by providing high quality, practice-based undergraduate and graduate educational programs in law, taxation, business and related professions. Many of its courses are taug...
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, will introduce two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single-threaded, you can effectively identify hot spots in your serverless code. In his session at @DevOpsSummit at 21st Cloud Expo, Dave Martin, Product owner at CA Technologies, will give a live demonstration and code walkthrough, showing how ...
Docker containers have brought great opportunities to shorten the deployment process through continuous integration and the delivery of applications and microservices. This applies equally to enterprise data centers as well as the cloud. In his session at 20th Cloud Expo, Jari Kolehmainen, founder and CTO of Kontena, discussed solutions and benefits of a deeply integrated deployment pipeline using technologies such as container management platforms, Docker containers, and the drone.io Cl tool. H...
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...